Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21. Epub 2007 Mar 22.

3.
4.

Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.

van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV.

Adv Drug Deliv Rev. 2013 Oct;65(10):1284-98. doi: 10.1016/j.addr.2013.08.012. Epub 2013 Sep 6. Review.

PMID:
24018362
5.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A.

Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.

6.

Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.

Bartlett DW, Davis ME.

Bioconjug Chem. 2007 Mar-Apr;18(2):456-68. Epub 2007 Feb 28.

7.

Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug.

Beh CW, Seow WY, Wang Y, Zhang Y, Ong ZY, Ee PL, Yang YY.

Biomacromolecules. 2009 Jan 12;10(1):41-8. doi: 10.1021/bm801109g.

PMID:
19072631
8.

pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo.

Kolli S, Wong SP, Harbottle R, Johnston B, Thanou M, Miller AD.

Bioconjug Chem. 2013 Mar 20;24(3):314-32. doi: 10.1021/bc3004099. Epub 2013 Mar 7.

PMID:
23305315
9.
10.

Proteinase K-containing lipid nanoparticles for therapeutic delivery of siRNA LOR-1284.

Kim DC, Cho YA, Li H, Yung BC, Lee RJ.

Anticancer Res. 2014 Jul;34(7):3531-5.

PMID:
24982365
11.

The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery.

Yuan X, Shah BA, Kotadia NK, Li J, Gu H, Wu Z.

Pharm Res. 2010 Jul;27(7):1285-95. doi: 10.1007/s11095-010-0103-0. Epub 2010 Mar 23.

PMID:
20309616
12.

siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA.

Zuckerman JE, Gale A, Wu P, Ma R, Davis ME.

Nucleic Acid Ther. 2015 Apr;25(2):53-64. doi: 10.1089/nat.2014.0505. Epub 2015 Mar 3.

13.

Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.

Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN.

Acc Chem Res. 2012 Jul 17;45(7):1163-71. doi: 10.1021/ar300048p. Epub 2012 May 8.

PMID:
22568781
14.

A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.

Wang XL, Xu R, Lu ZR.

J Control Release. 2009 Mar 19;134(3):207-13. doi: 10.1016/j.jconrel.2008.11.010. Epub 2008 Nov 27.

PMID:
19135104
15.

SiRNA drug delivery by biodegradable polymeric nanoparticles.

Yuan X, Li L, Rathinavelu A, Hao J, Narasimhan M, He M, Heitlage V, Tam L, Viqar S, Salehi M.

J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2821-8.

PMID:
17048488
16.

Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.

Guo J, Cheng WP, Gu J, Ding C, Qu X, Yang Z, O'Driscoll C.

Eur J Pharm Sci. 2012 Apr 11;45(5):521-32. doi: 10.1016/j.ejps.2011.11.024. Epub 2011 Dec 11.

PMID:
22186295
17.

Recent patents in siRNA delivery employing nanoparticles as delivery vectors.

Nimesh S.

Recent Pat DNA Gene Seq. 2012 Aug;6(2):91-7. Review.

PMID:
22670609
18.

Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy.

Hallaj-Nezhadi S, Lotfipour F, Dass CR.

Pharmazie. 2010 Dec;65(12):855-9. Review.

PMID:
21284252
19.

A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.

Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, Zhou X, Liu C, Wang R, Zhang Q.

Biomaterials. 2012 Dec;33(34):8893-905. doi: 10.1016/j.biomaterials.2012.08.057. Epub 2012 Sep 12.

PMID:
22979990
20.

Different mechanisms for nanoparticle formation between pDNA and siRNA using polyrotaxane as the polycation.

Yamada Y, Hashida M, Nomura T, Harashima H, Yamasaki Y, Kataoka K, Yamashita A, Katoono R, Yui N.

Chemphyschem. 2012 Apr 10;13(5):1161-5. doi: 10.1002/cphc.201100800. Epub 2012 Mar 1. No abstract available.

PMID:
22383277

Supplemental Content

Support Center